Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Circulation ; 149(20): 1549-1564, 2024 May 14.
Article in English | MEDLINE | ID: mdl-38606558

ABSTRACT

BACKGROUND: Among patients with pulmonary arterial hypertension (PAH), acute vasoreactivity testing during right heart catheterization may identify acute vasoresponders, for whom treatment with high-dose calcium channel blockers (CCBs) is recommended. However, long-term outcomes in the current era remain largely unknown. We sought to evaluate the implications of acute vasoreactivity response for long-term response to CCBs and other outcomes. METHODS: Patients diagnosed with PAH between January 1999 and December 2018 at 15 pulmonary hypertension centers were included and analyzed retrospectively. In accordance with current guidelines, acute vasoreactivity response was defined by a decrease of mean pulmonary artery pressure by ≥10 mm Hg to reach <40 mm Hg, without a decrease in cardiac output. Long-term response to CCBs was defined as alive with unchanged initial CCB therapy with or without other initial PAH therapy and World Health Organization functional class I/II and/or low European Society of Cardiology/European Respiratory Society risk status at 12 months after initiation of CCBs. Patients were followed for up to 5 years; clinical measures, outcome, and subsequent treatment patterns were captured. RESULTS: Of 3702 patients undergoing right heart catheterization for PAH diagnosis, 2051 had idiopathic, heritable, or drug-induced PAH, of whom 1904 (92.8%) underwent acute vasoreactivity testing. A total of 162 patients fulfilled acute vasoreactivity response criteria and received an initial CCB alone (n=123) or in combination with another PAH therapy (n=39). The median follow-up time was 60.0 months (interquartile range, 30.8-60.0), during which overall survival was 86.7%. At 12 months, 53.2% remained on CCB monotherapy, 14.7% on initial CCB plus another initial PAH therapy, and the remaining patients had the CCB withdrawn and/or PAH therapy added. CCB long-term response was found in 54.3% of patients. Five-year survival was 98.5% in long-term responders versus 73.0% in nonresponders. In addition to established vasodilator responder criteria, pulmonary artery compliance at acute vasoreactivity testing, low risk status and NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels at early follow-up correlated with long-term response and predicted survival. CONCLUSIONS: Our data display heterogeneity within the group of vasoresponders, with a large subset failing to show a sustained satisfactory clinical response to CCBs. This highlights the necessity for comprehensive reassessment during early follow-up. The use of pulmonary artery compliance in addition to current measures may better identify those likely to have a good long-term response.


Subject(s)
Calcium Channel Blockers , Cardiac Catheterization , Pulmonary Arterial Hypertension , Humans , Female , Male , Middle Aged , Retrospective Studies , Pulmonary Arterial Hypertension/drug therapy , Pulmonary Arterial Hypertension/physiopathology , Pulmonary Arterial Hypertension/diagnosis , Pulmonary Arterial Hypertension/mortality , Treatment Outcome , Calcium Channel Blockers/therapeutic use , Pulmonary Artery/physiopathology , Pulmonary Artery/drug effects , Adult , Aged , Antihypertensive Agents/therapeutic use
2.
J Clin Med ; 12(19)2023 Sep 28.
Article in English | MEDLINE | ID: mdl-37834897

ABSTRACT

(1) Background: Long COVID syndrome (LCS) is a heterogeneous long-standing condition following COVID-19 infection. Treatment options are limited to symptomatic measures, and no specific medication has been established. Hyperbaric oxygenation (HBO) has been found to have a positive impact on the treatment of COVID-19 infection. This study evaluates both the feasibility and outcome of supportive HBO in patients with LCS. (2) Methods: Within 17 months, 70 patients with proven LCS were prospectively included. Each patient underwent a cycle of 10 subsequent HBO treatment sessions administered for 75 min at 2.2 atmospheres. Evaluation of the patients was performed before the first and after the last HBO session and 3 months afterwards. Statistical evaluation was based on an intention-to-treat analysis using Fisher's exact test and Student's t-test for paired samples. (3) Results: In total, 59 patients (33 females, 26 males; mean age: 43.9 years; range: 23-74 years; median: 45.0) were evaluable. After HBO, a statistically significant improvement of physical functioning (p < 0.001), physical role (p = 0.01), energy (p < 0.001), emotional well-being (p < 0.001), social functioning (p < 0.001), pain (p = 0.01) and reduced limitation of activities (p < 0.001) was confirmed. (4) Conclusions: Physical functioning and both the physical and emotional role improved significantly and sustainably, suggesting HBO as a promising supportive therapeutic tool for the treatment of LCS.

3.
Pediatr Nephrol ; 38(9): 3117-3127, 2023 09.
Article in English | MEDLINE | ID: mdl-36943467

ABSTRACT

BACKGROUND: Tumor lysis syndrome (TLS) and its most serious complication, acute kidney injury (AKI) are one of the emergency conditions in onco-hematology. It is difficult to predict the degree of kidney involvement. Therefore, we studied children with leukemia and lymphoma treated in four Hungarian tertiary centers (inpatient university clinics) retrospectively (2006-2016) from a nephrological aspect. METHOD: Data of 31 pediatric patients were obtained from electronic- and paper-based medical records. Physical status, laboratory test results, treatments, and outcomes were assessed. Patients were analyzed according to both "traditional" TLS groupings, as laboratory TLS or clinical TLS, and nephrological aspect based on pRIFLE classification, as mild or severe AKI. RESULTS: Significant differences were found between the changes in parameters of phosphate homeostasis and urea levels in both classifications. Compared to age-specific normal phosphate ranges, before the development of TLS, hypophosphatemia was common (19/31 cases), while in the post-TLS period, hyperphosphatemia was observed (26/31 cases) most frequently. The rate of daily change in serum phosphate level was significant in the nephrological subgroups, but peaks of serum phosphate level show only a moderate increase. The calculated cut-off value of daily serum phosphate level increased before AKI was 0.32 mmol/L per ROC analysis for severe TLS-AKI. The 24-h urinalysis data of eight patients revealed transiently increased phosphate excretion only in those patients with TLS in whom serum phosphate was elevated in parallel. CONCLUSION: Daily serum phosphate level increase can serve as a prognostic factor for the severity of pediatric TLS, as well as predict the severity of kidney involvement. A higher resolution version of the Graphical abstract is available as Supplementary information.


Subject(s)
Acute Kidney Injury , Leukemia , Lymphoma , Tumor Lysis Syndrome , Humans , Child , Tumor Lysis Syndrome/etiology , Tumor Lysis Syndrome/complications , Retrospective Studies , Leukemia/complications , Lymphoma/complications , Lymphoma/diagnosis , Acute Kidney Injury/etiology , Acute Kidney Injury/complications , Phosphates , Kidney
4.
Orv Hetil ; 163(27): 1074-1081, 2022 Jul 03.
Article in Hungarian | MEDLINE | ID: mdl-35895468

ABSTRACT

Introduction: According to the recommendation of the American Thyroid Association 2015 guideline, the treatment of 1-4 cm (T1b-2) low-risk differentiated thyroid cancer (DTC) is lobectomy without radioiodine therapy. Objective: Retrospective analysis of multifocality in surgical and histological data of T1-2 patients living on moderate iodine intake. Methods: Analysis of the pathological characterisation of 81 low-risk (T1-2) DTC patients who underwent total thy-roidectomy. Patients were treated at Flor Ferenc Hospital, Kistarcsa, Hungary, between 2013 and 2019. Results: 64 patients had T1, while 17 patients had T2 status. 65/81 (80.2%) patients had papillary, and 16/81 (19.8%) had follicular subtype. Lymph node metastasis was detected up to 18.4% in papillary and 18% in follicular patients. Multifocal tumours were detected in 25% (16/64) of T1 patients, of these 10.9% (7/64) was unilateral and 14.1% (9/64) was bilateral. Multifocal tumours were detected in 11.7% (2/17) of T2 patients; both were bilateral. Distribution of T1-2 bilateral multifocal patients (11/81; 13.5%) was n = 3 T1a-, n = 6 T1b and n = 2 T2 stadium, from these 10 patients received radioiodine treatment. The sizes of contralateral tumours were <5 mm in 9 patients, and >5 mm in 2 patients. Conclusions: Due to the frequent (13.5%) bilateral multifocality in T1-2 DTC patients, we suggest total thyroidec-tomy instead of lobectomy. After lobectomy, the follow-up of the contralateral tumours is almost impossible by ul-trasonography due to the small tumour size (on average 2.8 mm) and frequently detected benign nodules; therefore the multifocality might remain undetected, which can distort the plan for adjuvant treatment.


Subject(s)
Adenocarcinoma , Thyroid Neoplasms , Adenocarcinoma/surgery , Humans , Iodine Radioisotopes/therapeutic use , Lymphatic Metastasis , Retrospective Studies , Thyroid Neoplasms/pathology , Thyroidectomy
5.
Neuropsychopharmacol Hung ; 22(2): 56-59, 2020 Jun.
Article in Hungarian | MEDLINE | ID: mdl-32683329

ABSTRACT

Nowadays the role of nutrition is increasingly appreciated in the development of the various mental disorders as well as in employing effi cacious therapies. Realizing this development and following international professional examples we have established the Hungarian Psychiatric Association's Nutritional Science Section in 2018. Our present paper reports on the connection between mental disorders and nutrition, reviewing the relevant literature from two directions. On the one hand, insuffi cient consumption of essential micronutrients, trace elements, (pro) vitamins cause defi ciencies leading to disrupted production and function of essential enzymes and neurotransmitters and consequentially to emergence of psychopathological symptoms as well as impeding the development of eff ect of adequately administered psychopharmacons and the effi ciency and success of pharmacotherapy. On the other hand, our paper also reviews potentially dangerous pharmacokinetic and pharmacodynamic interactions of nutraceuticals and dietary supplements used for health prevention purposes in parallel to pharmacotherapies which may infl uence or decrease eff ectiveness of medications.


Subject(s)
Nutrition Assessment , Dietary Supplements , Humans , Mental Disorders , Micronutrients , Trace Elements , Vitamins
6.
Orv Hetil ; 158(51): 2041-2047, 2017 Dec.
Article in Hungarian | MEDLINE | ID: mdl-29250970

ABSTRACT

INTRODUCTION AND AIM: To implement lipiodol as a fiducial marker of the tumor bed for image-guided radiotherapy with simultaneous integrated boost technique as part of radiochemotherapy for muscle invasive bladder tumors. METHOD: Since April 2016, radiochemotherapy was performed in 3 male patients with muscle invasive, transitional cell bladder carcinoma. Prior to radiochemotherapy, tumor bed resection was performed for each patient, at the same time 10 ml of lipiodol solution was injected submucosally into the resection site, thus marking the tumor bed for escalated dose irradiation. During radiochemotherapy 51 Gy (1.7 Gy/die) to the pelvis, 57 Gy (1.9 Gy/die) to the whole bladder, and 63 Gy (2.1 Gy/die) to the lipiodol-labeled tumor bed was delivered with simultaneous integrated boost technique. The accuracy of the irradiation was controlled by daily kilovoltage CT. Early radiogenic urogenital and gastrointestinal side effects were recorded according to Radiation Therapy Oncology Group side-effects grading recommendation. RESULTS: Substantial perioperative side effect or toxicity were not observed during and after the injection of lipiodol. The prescribed dose was successfully delivered in all patients. Radiotherapy duration was 6 weeks. The lipiodol-labeled tumor bed was clearly visible on daily kilovoltage cone beam CT. In one patient grade II cystitis and proctitis was observed, another patient experienced only grade I cystitis. These complaints improved with symptomatic medication. In the third patient no significant side effect occurred. CONCLUSIONS: The injection of lipiodol into the bladder wall is a safe technique, without any perioperative toxicity or complication. The tumor bed demarcated by lipiodol was visible both on treatment planning and kilovoltage CTs. The total treatment time was shortened by 4 days. The treatment was well tolerated, early side effects were moderate, or slight. Orv Hetil. 2017; 158(51): 2041-2047.


Subject(s)
Contrast Media/administration & dosage , Ethiodized Oil/administration & dosage , Radiotherapy, Image-Guided/methods , Radiotherapy, Intensity-Modulated/methods , Urinary Bladder Neoplasms/radiotherapy , Administration, Intravesical , Chemoradiotherapy , Humans , Male , Urologic Surgical Procedures/methods
7.
Brain Struct Funct ; 221(7): 3803-23, 2016 09.
Article in English | MEDLINE | ID: mdl-26843217

ABSTRACT

Neuronal calcium-binding protein 1 and -2 (NECAB1/2) localize to multiple excitatory neuron populations in the mouse spinal cord. Here, we analyzed rat and human spinal cord, combining in situ hybridization and immunohistochemistry, complementing newly collated data on mouse spinal cord for direct comparisons. Necab1/2 mRNA transcripts showed complementary distribution in rodent's spinal cord. Multiple-labeling fluorescence histochemistry with neuronal phenotypic markers localized NECAB1 to a dense fiber plexus in the dorsal horn, to neurons mainly in superficial layers and to commissural interneurons in both rodent species. NECAB1-positive (+) motor neurons were only found in mice. NECAB1 distribution in the human spinal cord was similar with the addition of NECAB1-like immunoreactivity surrounding myelinated axons. NECAB2 was mainly present in excitatory synaptic boutons in the dorsal horn of all three species, and often in calbindin-D28k(+) neuronal somata. Rodent ependymal cells expressed calbindin-D28k. In humans, they instead were NECAB2(+) and/or calretinin(+). Our results reveal that the association of NECAB2 to excitatory neuronal circuits in the spinal cord is evolutionarily conserved across the mammalian species investigated so far. In contrast, NECAB1 expression is more heterogeneous. Thus, our study suggests that the phenotypic segregation of NECAB1 and -2 to respective excitatory and inhibitory spinal systems can underpin functional modalities in determining the fidelity of synaptic neurotransmission and neuronal responsiveness, and might bear translational relevance to humans.


Subject(s)
Calcium-Binding Proteins/metabolism , Eye Proteins/metabolism , Mixed Function Oxygenases/metabolism , Neurons/metabolism , Spinal Cord/metabolism , Animals , Calbindin 1/metabolism , Calbindin 2/metabolism , Glutamate Decarboxylase/metabolism , Humans , Male , Mice, Inbred C57BL , Motor Neurons/metabolism , Protein Kinase C/metabolism , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Receptors, Somatostatin/metabolism , Synaptophysin/metabolism , Vesicular Glutamate Transport Protein 2/metabolism
8.
J Neurol Neurosurg Psychiatry ; 85(12): 1386-95, 2014 Dec.
Article in English | MEDLINE | ID: mdl-24899728

ABSTRACT

In multiple sclerosis (MS), diffuse degenerative processes in the deep grey matter have been associated with clinical disabilities. We performed a systematic study in MS deep grey matter with a focus on the incidence and topographical distribution of lesions in relation to white matter and cortex in a total sample of 75 MS autopsy patients and 12 controls. In addition, detailed analyses of inflammation, acute axonal injury, iron deposition and oxidative stress were performed. MS deep grey matter was affected by two different processes: the formation of focal demyelinating lesions and diffuse neurodegeneration. Deep grey matter demyelination was most prominent in the caudate nucleus and hypothalamus and could already be seen in early MS stages. Lesions developed on the background of inflammation. Deep grey matter inflammation was intermediate between low inflammatory cortical lesions and active white matter lesions. Demyelination and neurodegeneration were associated with oxidative injury. Iron was stored primarily within oligodendrocytes and myelin fibres and released upon demyelination. In addition to focal demyelinated plaques, the MS deep grey matter also showed diffuse and global neurodegeneration. This was reflected by a global reduction of neuronal density, the presence of acutely injured axons, and the accumulation of oxidised phospholipids and DNA in neurons, oligodendrocytes and axons. Neurodegeneration was associated with T cell infiltration, expression of inducible nitric oxide synthase in microglia and profound accumulation of iron. Thus, both focal lesions as well as diffuse neurodegeneration in the deep grey matter appeared to contribute to the neurological disabilities of MS patients.


Subject(s)
Demyelinating Diseases/pathology , Gray Matter/pathology , Inflammation/pathology , Iron/chemistry , Multiple Sclerosis/pathology , Adult , Aged , Aged, 80 and over , Brain/pathology , Brain Chemistry , Case-Control Studies , Caudate Nucleus/pathology , Disease Progression , Female , Humans , Hypothalamus/pathology , Male , Middle Aged , Retrospective Studies , White Matter/pathology
9.
Br J Haematol ; 166(3): 410-20, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24712521

ABSTRACT

High-dose methotrexate (HD-MTX) plays an important role in the consolidation therapy of acute lymphoblastic leukaemia (ALL) in many treatment regimens worldwide. However, there is a large interpatient variability in the pharmacokinetics and toxicity of the drug. We investigated the influence of single nucleotide polymorphisms (SNPs) in genes of the folate metabolic pathway, transporter molecules and transcription proteins on the pharmacokinetics and toxicity of MTX and 7-hydroxy-methotrexate (7-OH-MTX). 63 SNPs of 14 genes were genotyped and a total of 463 HD-MTX courses (administered according to the ALL-BFM 95 and ALL IC-BFM 2002 protocols) were analysed. Haematological, hepatic and renal toxicities, estimated by routine laboratory parameters were evaluated. Random forest and regression trees were used for variable selection and model building. Linear mixed models were established to prove the significance of the selected variables. SNPs (rs4948502, rs4948496, rs4948487) of the ARID5B gene were associated with the serum levels of MTX (P < 0·02), serum levels and area under the curve of 7-OH-MTX (P < 0·02) and with hypoproteinaemia (P = 0·004). SLCO1B1 rs4149056 also showed a significant association with serum MTX levels (P < 0·001). Our findings confirm the association of novel genetic variations in folate-related and ARID5B genes with the serum MTX levels and acute toxicity.


Subject(s)
DNA-Binding Proteins/genetics , Genetic Variation , Methotrexate/adverse effects , Methotrexate/pharmacokinetics , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics , Transcription Factors/genetics , Adolescent , Alleles , Antimetabolites, Antineoplastic/administration & dosage , Antimetabolites, Antineoplastic/adverse effects , Antimetabolites, Antineoplastic/pharmacokinetics , Child , Child, Preschool , DNA-Binding Proteins/metabolism , Female , Folic Acid/metabolism , Gene Frequency , Genotype , Humans , Infant , Male , Methotrexate/administration & dosage , Pharmacogenetics , Polymorphism, Single Nucleotide , Precursor Cell Lymphoblastic Leukemia-Lymphoma/metabolism , Transcription Factors/metabolism
10.
Acta Neuropathol Commun ; 1: 72, 2013 Nov 11.
Article in English | MEDLINE | ID: mdl-24252716

ABSTRACT

BACKGROUND: Human prion diseases are a group of rare fatal neurodegenerative conditions with well-developed clinical and neuropathological diagnostic criteria. Recent observations have expanded the spectrum of prion diseases beyond the classically recognized forms. RESULTS: In the present study we report six patients with a novel, apparently sporadic disease characterised by thalamic degeneration and rapidly progressive dementia (duration of illness 2-12 months; age at death: 55-81 years). Light and electron microscopic immunostaining for the prion protein (PrP) revealed a peculiar intraneuritic distribution in neocortical regions. Proteinase K resistant PrP (PrPres) was undetectable by Western blotting in frontal cortex from the three cases with frozen tissue, even after enrichment for PrPres by centrifugation or by phosphotungstic acid precipitation. Conformation-dependent immunoassay analysis using a range of PK digestion conditions (and no PK digestion) produced only very limited evidence of meaningful D-N (denatured/native) values, indicative of the presence of disease-associated PrP (PrPSc) in these cases, when the results were compared with appropriate negative control groups. CONCLUSIONS: Our observation expands the spectrum of conditions associated with rapidly progressive dementia and may have implications for the understanding of the pathogenesis of prion diseases.


Subject(s)
Dementia/physiopathology , Endopeptidase K/metabolism , Neurodegenerative Diseases/physiopathology , Prions/metabolism , Thalamus/physiopathology , Aged , Aged, 80 and over , Cerebral Cortex/metabolism , Cerebral Cortex/pathology , Dementia/pathology , Disease Progression , Female , Humans , Male , Middle Aged , Neurodegenerative Diseases/pathology , Thalamus/pathology
11.
PLoS One ; 8(8): e69843, 2013.
Article in English | MEDLINE | ID: mdl-23940529

ABSTRACT

In this study we investigated whether polymorphisms in the folate pathway influenced the risk of childhood acute lymphoblastic leukemia (ALL) or the survival rate of the patients. For this we selected and genotyped 67 SNPs in 15 genes in the folate pathway in 543 children with ALL and 529 controls. The results were evaluated by gender adjusted logistic regression and by the Bayesian network based Bayesian multilevel analysis of relevance (BN-BMLA) methods. Bayesian structure based odds ratios for the relevant variables and interactions were also calculated. Altogether 9 SNPs in 8 genes were associated with altered susceptibility to ALL. After correction for multiple testing, two associations remained significant. The genotype distribution of the MTHFD1 rs1076991 differed significantly between the ALL and control population. Analyzing the subtypes of the disease the GG genotype increased only the risk of B-cell ALL (p = 3.52×10(-4); OR = 2.00). The GG genotype of the rs3776455 SNP in the MTRR gene was associated with a significantly reduced risk to ALL (p = 1.21×10(-3); OR = 0.55), which resulted mainly from the reduced risk to B-cell and hyperdiploid-ALL. The TC genotype of the rs9909104 SNP in the SHMT1 gene was associated with a lower survival rate comparing it to the TT genotype (80.2% vs. 88.8%; p = 0.01). The BN-BMLA confirmed the main findings of the frequentist-based analysis and showed structural interactional maps and the probabilities of the different structural association types of the relevant SNPs especially in the hyperdiploid-ALL, involving additional SNPs in genes like TYMS, DHFR and GGH. We also investigated the statistical interactions and redundancies using structural model properties. These results gave further evidence that polymorphisms in the folate pathway could influence the ALL risk and the effectiveness of the therapy. It was also shown that in gene association studies the BN-BMLA could be a useful supplementary to the traditional frequentist-based statistical method.


Subject(s)
Bayes Theorem , Folic Acid/metabolism , Polymorphism, Genetic/genetics , Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics , Precursor Cell Lymphoblastic Leukemia-Lymphoma/metabolism , Adolescent , Adult , Child , Child, Preschool , Female , Genetic Predisposition to Disease/genetics , Genotype , Haplotypes/genetics , Humans , Infant , Male , Methylenetetrahydrofolate Dehydrogenase (NADP)/genetics , Middle Aged , Minor Histocompatibility Antigens , Polymorphism, Single Nucleotide/genetics , Survival Rate , Young Adult
12.
Reprod Biol Endocrinol ; 11: 67, 2013 Jul 17.
Article in English | MEDLINE | ID: mdl-23866102

ABSTRACT

BACKGROUND: L-carnitine-mediated beta-oxidation of fatty acids has a well established role in energy supply of oocytes and embryos. Disturbed carnitine metabolism may impair the reproductive potential in IVF and can serve as a biomarker of pregnancy outcome. METHODS: Our study was performed between March 24, 2011 and May 9, 2011. We performed 44 unselected IVF cycles, (aged 23-40 years (mean: 32.3+/-5.1 years) and had BMI of 17.3-34.7 (mean: 23.80+/-4.9). Samples were also obtained from 18 healthy women of similar age admitted for minor elective surgery to serve as control for plasma carnitine profile. Serum and follicular fluid (FF) free carnitine (FC) and 20 major acylcarnitines (ACs) were measured by ESI/MS/MS method. RESULTS: Serum FC and AC levels in IVF patients were comparable to those in healthy control women. In FF FC and short-chain AC concentrations were similar to those in maternal serum, however, the levels of medium-chain, and long-chain AC esters were markedly reduced (p<0.05). The serum to FF ratio of individual carnitine compounds increased progressively with increasing carbon chain length of AC esters (p<0.05). There was a marked reduction in total carnitine, FC and AC levels of serum and FF in patients with oocyte number of >9 and/or with embryo number of >6 as compared to the respective values of <9 and/or <6 (p<0.05). CONCLUSIONS: In IVF patients with better reproductive potential the carnitine/AC pathway appears to be upregulated that may result in excess carintine consumption and relative depletion of carnitine pool. Consequently, IVF patients may benefit from carnitine supplementation.


Subject(s)
Carnitine/analogs & derivatives , Fertilization in Vitro , Follicular Fluid/chemistry , Adult , Carnitine/analysis , Carnitine/blood , Case-Control Studies , Embryo Transfer , Esters , Female , Humans , Male , Oocytes/chemistry , Oocytes/cytology , Pregnancy , Pregnancy Rate , Spectrometry, Mass, Electrospray Ionization , Sperm Injections, Intracytoplasmic , Young Adult
13.
Acta Neuropathol ; 122(2): 205-22, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21437732

ABSTRACT

Sporadic tauopathies are characterized by differential cellular and topographical predominance of phospho-tau immunoreactivity and biochemical distinction of the tau protein. Established entities include progressive supranuclear palsy, corticobasal degeneration, Pick's disease, and argyrophilic grain disease. During a community-based longitudinal study on aging, we detected tau pathologies not compatible with these categories. We immunostained for different phospho-tau epitopes, 4R and 3R tau isoforms, α-synuclein, amyloid-ß, and phospho-TDP-43, analyzed the MAPT and ApoE genes, and performed western blotting for the tau protein. The mean age of patients (4 women, 3 men) was 83.8 years. Clinical presentations combined dementia with psychiatric symptoms and/or parkinsonism. In addition to neurofibrillary tangles and diffuse neuronal cytoplasmic tau immunoreactivity, the neuropathology was characterized by peculiar cytopathologies (diffuse granular immunopositivity of astrocytic processes and patchy accumulation of thin threads) in a distinctive distribution (frontal and temporal cortices, hippocampus, amygdala, basal ganglia, locus coeruleus, and substantia nigra). Argyrophilic grains were detected in four patients. Few to moderate densities of neuritic plaques but widespread phospho-TDP-43 pathology was observed in five patients. There was variability in the H1/H2 and ApoE alleles and biochemical features of tau protein. We propose these cases as complex tauopathy with a characteristic constellation: some features of primary tauopathies and Alzheimer's disease mixed with additional cytopathologies including a distinctive astrogliopathy, in a characteristic distribution of lesions. These complex tauopathies in the elderly deserve specific diagnostic and eventually therapeutic considerations.


Subject(s)
Brain/pathology , Dementia/pathology , Tauopathies/pathology , tau Proteins/metabolism , Aged, 80 and over , Blotting, Western , Brain/metabolism , Dementia/metabolism , Female , Humans , Immunohistochemistry , Male , Protein Isoforms/metabolism , Tauopathies/metabolism
14.
Hepatogastroenterology ; 57(102-103): 1069-73, 2010.
Article in English | MEDLINE | ID: mdl-21410033

ABSTRACT

BACKGROUND/AIMS: Intravenous lipid emulsions may contribute to the development of total parenteral nutrition (TPN)--induced hepatobiliary complications. METHODS: In a prospective, randomised setting the authors compared the short-term hepatic effects of medium-chain triglycerides/short-chain triglycerides (MCT/LCT) physical mixture with a four-component intravenous (i.v.) lipid emulsion (LCT, MCT, Olive-oil and Fish-oil) in patients undergoing elective gastrointestial surgery during the early postoperative period. RESULTS: The authors demonstrated that total and conjugated bilirubin, alkaline phosphatase, alanine aminotransferase, aspartate amino transferase and cholinesterase did not change significantly during the 5-days observation period. In contrast to this, gamma-glutamyl transferase (GGT) activity increased by 2,4 times during 5-days therapy with the lipid emulsions mentioned above (SMOF lipid: 21,9 to 52,9 U/L, Lipofundin: from 32,5 to 79,6 U/L). CONCLUSION: during a 4-days administration hepatic effect of the intravenous lipid emulsions did not differ significantly. The changes in enzyme levels confirm the cholestatic type of hepatobiliary deviations without clinical impact on short-term TPN therapy.


Subject(s)
Fat Emulsions, Intravenous/adverse effects , Gastrointestinal Tract/surgery , Liver Diseases/etiology , Parenteral Nutrition, Total/adverse effects , Adult , Aged , Aged, 80 and over , Alanine Transaminase/blood , Female , Humans , Male , Middle Aged , Postoperative Period , Prospective Studies , gamma-Glutamyltransferase/blood
15.
Anticancer Res ; 28(5B): 3051-4, 2008.
Article in English | MEDLINE | ID: mdl-19031955

ABSTRACT

BACKGROUND: High-dose methotrexate (HD-MTX) is one of the most important agents in the therapy of osteosarcoma (OSC). Acute and delayed toxicities still constitute clinical problems. Methylenetetrahydrofolate reductase (MTHFR) has a key role in the folate cycle. In case of homozygosity of the 677C-->T polymorphism, treatment with antimetabolites, such as MTX, can cause additional toxicity. CASE REPORT: In the present work, we describe the case of a 10-year-old boy with OSC. After the first HD-MTX infusion (12 g/m2/6 h) acute neurological disturbances were detected followed by severe hepatotoxicity. Plasma concentrations of MTX and 7-OH-MTX showed delayed clearance. Calcium folinate was administered to the patient until +186 hours. Tha patient was homozygous for the 677 polymorphism and wild-type for the 1298 polymorphism of the MTHFR gene. CONCLUSION: We hypothesize that MTX toxicity can be explained by the association between homozygosity of the MTHFR C677T polymorphism causing disturbances in the folate status and thus an enhanced vulnerability of the central nervous system to antimetabolites and to the prolonged MTX exposure due to delayed MTX clearance.


Subject(s)
Antimetabolites, Antineoplastic/adverse effects , Antimetabolites, Antineoplastic/pharmacokinetics , Bone Neoplasms/drug therapy , Methotrexate/adverse effects , Methotrexate/pharmacokinetics , Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Neurotoxicity Syndromes/etiology , Osteosarcoma/drug therapy , Antimetabolites, Antineoplastic/administration & dosage , Bone Neoplasms/enzymology , Bone Neoplasms/genetics , Child , Dose-Response Relationship, Drug , Humans , Male , Methotrexate/administration & dosage , Methylenetetrahydrofolate Reductase (NADPH2)/metabolism , Neurotoxicity Syndromes/metabolism , Osteosarcoma/enzymology , Osteosarcoma/genetics , Polymorphism, Genetic
16.
Magy Onkol ; 52(3): 283-91, 2008 Sep.
Article in Hungarian | MEDLINE | ID: mdl-18845499

ABSTRACT

Primary genetic abnormalities of leukemia cells have important prognostic significance in childhood acute leukemia. In the last two years 30 newly diagnosed or recurrent childhood ALL bone marrow samples were analyzed for chromosomal abnormalities with conventional G-banding and interphase-fluorescence in situ hybridization (I-FISH) using probes to detect BCR/ABL fusions, cryptic TEL/AML1 and MLL rearrangements and p16(9p21) tumor suppressor gene deletions. G-banded karyotype analysis found clonal chromosomal aberrations in 50% of cases. With the use of complementary I-FISH techniques, ALL-specific structural and numerical changes could be identified in 70% of the patients. Nine cases (30%) had subtle chromosomal aberrations with prognostic importance that had not been detected in G-banded analysis. Conventional G-banding yielded additional information (rare and complex structural aberrations) in 19% of patients. The most common aberration (30%) was AML1 copy number increase present in G-banded hyperdiploid karyotype as a chromosome 21 tetrasomy in the majority of cases; one case displayed 5-6 copies and in another case amplification of AML1 gene on der(21) was combined with TEL/AML1 fusion of the homologue AML1 gene and deletion of the remaining TEL allele. High hiperdiploidy was detected in 6 cases, in one patient with normal G-banding karyotype. TEL/AML1 fusion signals were identified in four patients. Deletion of p16 locus was found in eight cases (23%), of which only two had cytogenetically visible rearrangements. G-banding in combination with I-FISH has produced major improvements in the sensitivity and accuracy of cytogenetic analysis of ALL patients and this method helps to achieve a more precise identification of different risk categories in order to choose the optimal treatment.


Subject(s)
Chromosome Aberrations , Chromosomes, Human, Pair 21 , Gene Rearrangement , In Situ Hybridization, Fluorescence , Oncogene Proteins, Fusion/genetics , Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , Adolescent , Child , Child, Preschool , Chromosome Banding , Core Binding Factor Alpha 2 Subunit/genetics , Female , Fusion Proteins, bcr-abl/genetics , Gene Deletion , Histone-Lysine N-Methyltransferase , Humans , Interphase , Karyotyping/methods , Male , Myeloid-Lymphoid Leukemia Protein/genetics , Predictive Value of Tests , Prognosis , Proto-Oncogene Proteins c-ets/genetics , Repressor Proteins/genetics , Risk Factors , Sensitivity and Specificity , ETS Translocation Variant 6 Protein
17.
Orv Hetil ; 145(44): 2227-30, 2004 Oct 31.
Article in Hungarian | MEDLINE | ID: mdl-15626167

ABSTRACT

INTRODUCTION: Community-acquired pneumonia is a common cause of morbidity and mortality throughout the world. Moxifloxacin, a new generation fluoroquinolone have become an attractive therapeutic alternative in the treatment of community-acquired pneumonia because of its excellent pharmacokinetic parameters and wide antimicrobial spectrum. AIMS: The authors reviewed the role of moxifloxacin in the treatment of community-acquired pneumonia based on their experience and the data of the literature. METHODS: The authors studied the clinical outcome of the patients treated with moxifloxacin due to community-acquired pneumonia in their hospital ward between May 1, 2002 and May 1, 2003. RESULTS: Four patients with pneumonia were treated ineffectively by moxifloxacin during a year. Serious clinical and radiological progression occurred to each patient despite moxifloxacin therapy, and two patients had to be admitted to intensive care unit. Three patients were successfully treated by 2nd or 3rd generation cephalosporin and clarithromycin, but one patient died. CONCLUSIONS: The authors call attention with these cases to the fact that in clinical trials oral moxifloxacin therapy was not more efficient either clinically or microbiologically than standard therapy in the treatment of community-acquired pneumonia. Moxifloxacin therapy is recommended to be reserved to patients allergic or not responsive to other antibiotics, and in the case of infections due to penicillin-resistant pneumococci.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Aza Compounds/therapeutic use , Pneumonia, Bacterial/drug therapy , Quinolines/therapeutic use , Adult , Community-Acquired Infections/drug therapy , Female , Fluoroquinolones , Humans , Legionnaires' Disease/drug therapy , Male , Middle Aged , Moxifloxacin , Pneumonia, Bacterial/diagnosis , Pneumonia, Bacterial/diagnostic imaging , Radiography , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL